March 10, 2023
The Age-Related Disease Therapeutics Summit will once again be held in San Francisco this year, and Lifespan.io readers are encouraged to use the code 32026Lifespan when signing up. The full press release is included here. Are you up to date on the latest research and developments in therapeutic modalities, disease indications and 3D cell models...
February 21, 2023
The Alliance for Longevity Initiatives (A4LI) would like to applaud the efforts of Congressman Gus Bilirakis (R-FL) and Congressman Paul Tonko (D-NY) for co-chairing and launching the newly formed bipartisan Congressional Caucus for Longevity Science. The “Longevity Science Caucus” aims to increase funding for aging and longevity biotechnology, streamline regulations, and promote initiatives to increase...
February 08, 2023
The company cellvie, part of the portfolio of biotechnology holding company Kizoo Technology Capital, recently received $5.5 million to develop a mitochondria-based therapy. The full press release is included here. cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard Medical School, closes a $5.5 Million financing to get Series A-ready by the...
January 24, 2023
A Longevity Investors Lunch hosted by Maximon, Longevity Investors Conference, and Biolytica has been hosted at a satellite event of the well-known Davos conference. The press release is included here. Longevity stays in the limelight on the streets of Davos for the second time during this year’s World Economic Forum (WEF). The world is growing...
January 24, 2023
Open Longevity Foundation has announced Open Genes, a database of longevity-associated genes and a tool for future anti-aging therapy development. The full press release is included here. Open Longevity Foundation released a novel database of genes involved in human aging and longevity — Open Genes. It includes information of more than 2,400 genes, which is...
January 10, 2023
Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. As part of this research collaboration, the companies will leverage Pfizer's expertise and Gero’s technology platform with the aim to identify genes and...
